When a pregnant woman undergoes prenatal testing, the central question is rarely about technology. It is about what clinicians are actually looking for—and what they might miss. Two tests dominate the landscape: fetal ultrasound, which uses sound waves to map anatomy, and chromosomal microarray, which reads the genome for missing or extra segments of DNA. Each catches anomalies the other cannot see. Understanding how they work, and where they fall short, matters for every clinician who counsels expectant parents.

Two Tests, One Question: What Are We Actually Looking For?

Fetal ultrasound and genetic microarray answer different diagnostic questions. Ultrasound examines structure: the four chambers of the heart, the curve of the spine, the contour of the brain's ventricles. It can detect a cleft lip, a spina bifida lesion, or a missing kidney. But it cannot read the genome. Microarray, by contrast, detects copy-number variants—deletions or duplications of chromosomal segments that are too small for a traditional karyotype to see. It can identify the 22q11.2 deletion that causes DiGeorge syndrome, or the 1p36 deletion associated with intellectual disability. Yet it cannot see a heart defect that has no genomic signature.

The tension between these two modalities is not a flaw; it is a feature of how prenatal diagnosis has evolved. Structural anomalies visible on ultrasound often prompt a microarray to look for an underlying genetic cause. Conversely, a family history of genetic syndrome may lead to microarray even when the ultrasound appears normal. Fetal medicine specialists sit at this intersection, weighing the probability of a structural lesion against the likelihood of a genomic one.

Clinicians must decide which test to order first, and whether to order both. The decision depends on the clinical scenario: a routine low-risk pregnancy typically receives only ultrasound. But when an anomaly is found, or when parental anxiety or family history raises concern, microarray adds information that can change management. The question is not which test is better, but what each is designed to find.

How Ultrasound Maps the Fetal Body in Real Time

Fetal ultrasound works by emitting high-frequency sound waves that reflect off tissue boundaries—the interface between fluid and solid tissue, or between bone and soft tissue. The returning echoes are converted into a real-time image. The standard 20-week anatomy scan, also called the mid-trimester scan, surveys the fetal brain, spine, heart, stomach, kidneys, bladder, limbs, and umbilical cord. It is the most widely used prenatal screening tool in high-income countries.

Detection rates for major structural anomalies vary. A 2023 systematic review in the British Journal of Obstetrics and Gynaecology estimated that ultrasound identifies roughly 50 to 70 percent of significant structural abnormalities, depending on the organ system. Cardiac defects are among the most commonly missed, with detection rates sometimes below 50 percent. Operator skill, maternal body habitus, fetal position, and the timing of the scan all influence accuracy. A single scan is not definitive; repeat scans or referral to a specialist unit can improve detection.

What ultrasound cannot do is detect most genetic syndromes that do not produce visible structural changes. A fetus with a 22q11.2 deletion may have a normal anatomy scan. A fetus with a pathogenic variant in a gene for neurodevelopmental disorder may show no physical signs until after birth. This limitation is not a failure of the technology; it is a boundary of the method. Ultrasound sees anatomy, not DNA.

Microarray: Reading the Genome for Copy-Number Variants

Chromosomal microarray analysis detects submicroscopic deletions and duplications—copy-number variants—across the genome. It does so by comparing a fetal DNA sample, obtained via amniocentesis or chorionic villus sampling, to a reference genome. The resolution is far higher than a traditional karyotype, which can only see changes larger than about 5 to 10 megabases. Microarray can detect deletions as small as 50 to 100 kilobases, depending on the platform.

This sensitivity allows microarray to identify syndromes that karyotype would miss. The 22q11.2 deletion, responsible for DiGeorge syndrome, is the most common microdeletion, occurring in roughly 1 in 4,000 live births. Other examples include the 1p36 deletion (associated with intellectual disability and seizures) and the 15q11.2 deletion (linked to autism and developmental delay). Microarray also detects duplications, such as those at 16p11.2, which carry elevated risk for schizophrenia and autism.

Typical turnaround time is 7 to 14 days from sample receipt. This delay can be stressful for parents awaiting results after an abnormal ultrasound. Some centers now offer rapid microarray with results in 3 to 5 days for urgent cases. However, microarray cannot detect point mutations, balanced translocations, or triploidies. It also cannot predict the severity of conditions with variable expressivity. A 22q11.2 deletion can cause anything from a mild palate abnormality to severe cardiac disease and immune deficiency.

The UK National Screening Committee’s 2025 Evidence Review

In early 2025, the UK National Screening Committee published an updated evidence review on the use of microarray in prenatal diagnosis. The review examined accuracy, clinical utility, and cost-effectiveness. It found that, in pregnancies with a structural anomaly on ultrasound, microarray detects a clinically significant copy-number variant in roughly 6 percent of cases where karyotype was normal. This incremental yield is consistent with earlier studies from the United States and Europe.

Based on this evidence, the committee recommended that microarray should be offered to all pregnant women when a structural anomaly is identified. It stopped short of recommending universal offer in low-risk pregnancies, citing insufficient data on cost-effectiveness and the potential for detecting variants of unknown significance that cause parental anxiety. The committee noted that the psychological harms of uncertain results must be weighed against the benefits of diagnosis.

Cost-effectiveness modeling is ongoing. A 2024 health technology assessment from the UK's National Institute for Health and Care Excellence (NICE) estimated that offering microarray for all pregnancies with anomalies would cost roughly £350 per additional diagnosis, compared to karyotype alone. Whether that represents good value depends on the severity of the conditions detected and the availability of postnatal interventions. The committee emphasized that decisions should be made in consultation with a clinical geneticist or fetal medicine specialist.

When Ultrasound Finds Nothing but the Family History Whispers

A normal anatomy scan does not rule out genetic syndromes. This is especially relevant when the family history includes intellectual disability, autism, or known genetic conditions. In such cases, some clinicians offer microarray even without a structural anomaly. The American College of Medical Genetics and Genomics (ACMG) recommends that microarray be offered as first-tier testing for any pregnancy with one or more major structural anomalies identified by ultrasound. For pregnancies without anomalies but with concerning family history, the recommendation is less uniform.

Parental anxiety can drive microarray requests. A 2022 survey of obstetricians in the United States found that roughly 40 percent had ordered microarray for a patient with no ultrasound findings, primarily due to maternal request. The test's ability to detect variants of unknown significance (VUS) complicates counseling. A VUS is a copy-number variant that has not yet been classified as benign or pathogenic. It can cause uncertainty and worry, and sometimes leads to additional testing of parents to clarify inheritance.

Some centers have adopted microarray as first-tier testing for any indication—anomaly or not—citing the incremental yield and the desire to avoid missed diagnoses. A 2023 study from Columbia University found that, in a cohort of low-risk pregnancies, microarray detected a clinically significant variant in about 1.2 percent of cases with normal ultrasound. The debate continues about whether that yield justifies the costs and the anxiety from VUS results. The answer likely depends on the population and the resources available for genetic counseling.

The UAE’s Large-Scale Premarital Screening as a Parallel Model

A different approach to genomic screening comes from the United Arab Emirates. A report published in the New England Journal of Medicine in July 2026 described a national premarital genetic screening program that tests couples for recessive disease carrier status before conception. The program screens for hundreds of genes associated with severe autosomal recessive conditions, such as spinal muscular atrophy and cystic fibrosis. Couples who are both carriers for the same condition receive counseling about reproductive options, including preimplantation genetic testing or prenatal diagnosis.

This model shifts the focus from fetal diagnosis to prevention. Instead of waiting for an ultrasound to find a structural anomaly, or for a microarray to detect a deletion, the UAE program identifies risk before pregnancy begins. The program is large-scale: as of mid-2026, over 100,000 individuals had been screened. The reported detection rate for at least one recessive condition is roughly 20 percent, meaning about 1 in 5 individuals carries a mutation that could cause disease in offspring if the partner carries the same mutation.

The program illustrates how genomic screening can precede pregnancy, but it does not replace ultrasound or microarray. Many structural anomalies are not caused by recessive mutations. Neural tube defects, for example, have a multifactorial etiology involving folate status and environmental factors. And many copy-number variants arise de novo, meaning they are not inherited from either parent. The UAE model is complementary, not competitive. It adds a layer of prevention for a subset of conditions, while ultrasound and microarray remain essential for detecting anomalies and de novo variants.

Trade-Offs and Counter-Arguments: When More Information Harms

Despite the clear benefits of microarray, not all clinicians advocate for its routine use. Critics point to the problem of variants of unknown significance, which can cause prolonged anxiety and lead to unnecessary follow-up testing. A 2021 study in Prenatal Diagnosis found that VUS results were reported in roughly 2 to 3 percent of prenatal microarrays, and while most were eventually reclassified as benign, the interim period was stressful for families. Some argue that the psychological burden outweighs the diagnostic yield in low-risk populations.

Another concern is the potential for incidental findings—genetic variants that predispose to adult-onset conditions, such as certain cancer syndromes. While professional guidelines recommend not reporting such findings in prenatal settings unless they are medically actionable in childhood, there is variability in practice. A survey of genetic counselors in 2023 found that about 15 percent of respondents had encountered a case where an incidental finding was inadvertently disclosed, leading to complex ethical discussions about the child's future autonomy.

On the ultrasound side, the detection of soft markers—minor anatomical variations that are often benign—can also cause distress. Examples include an echogenic intracardiac focus or a choroid plexus cyst. These findings are typically resolved with follow-up scans, but the initial notification can provoke significant anxiety. A 2022 meta-analysis in Ultrasound in Obstetrics & Gynecology estimated that roughly 5 to 10 percent of routine anatomy scans identify at least one soft marker, and the vast majority of these pregnancies result in healthy outcomes. Yet the emotional toll on parents is real.

These trade-offs highlight the importance of informed consent and shared decision-making. Clinicians must explain not only what a test can find, but what it might find that is uncertain or incidental. The goal is not to maximize information at any cost, but to provide information that is actionable and aligned with the patient's values. Some families prefer to know everything possible; others prefer to avoid the potential for ambiguous results. Both perspectives are valid, and the clinical approach should respect that diversity.

Practical Takeaway: Matching Test to Clinical Scenario

No single prenatal test covers all possibilities. Ultrasound remains first-line for structural screening in all pregnancies. When an anomaly is found, microarray adds diagnostic value by identifying an underlying genetic cause in roughly 6 percent of cases. In low-risk pregnancies with normal ultrasound, the yield of microarray is much lower, and the decision to offer it depends on family history and parental preference.

Clinicians should counsel patients about the limitations of each test. Ultrasound cannot detect most genetic syndromes. Microarray cannot detect point mutations, balanced rearrangements, or some types of mosaicism. And both tests can produce results that are uncertain—a VUS on microarray, or a soft marker on ultrasound that resolves without consequence. Shared decision-making should include a discussion of what each test can and cannot find, and what the results might mean for the pregnancy and beyond.

Looking forward, the field may combine cell-free DNA screening with microarray-like resolution for copy-number variants, potentially reducing the need for invasive testing. Several companies are developing such assays, but clinical validation is still early. For now, the partnership between ultrasound and microarray remains the standard of care. Each test answers a different part of the question, and together they provide a more complete picture than either alone.

This article is for informational purposes only and does not constitute medical advice. Pregnant individuals should discuss their specific risks and testing options with a qualified healthcare provider.